The global nuclear medicine and radiopharmaceuticals market is expected to grow significantly, projected to reach USD 9.4 billion by 2028, up from USD 5.5 billion in 2023, at a CAGR of 11.3%. This growth presents strategic opportunities for healthcare executives in early diagnostics and precision treatments, particularly as the prevalence of cancer and cardiovascular diseases increases. Market insights indicate that the diagnostic segment is poised for near-term growth, while therapeutic applications represent long-term potential. North America currently leads the market, but the Asia-Pacific region is emerging as a significant area for expansion. Challenges such as cost pressures are prompting executives to pursue joint ventures, local isotope production, and value-based care models. The competitive landscape remains consolidated but is evolving, with major players like GE HealthCare and Bayer alongside emerging companies creating new opportunities through partnerships and acquisitions. Overall, nuclear medicine is seen as a critical component for future growth and differentiation in the healthcare sector.
Fri, 19 Sep 2025 02:30:23 GMT | The Globe and Mail